Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd...

Descripción completa

Detalles Bibliográficos
Autores principales: Alder, Laura, Trapani, Dario, Bradbury, Claire, Van Swearingen, Amanda E. D., Tolaney, Sara M., Khasraw, Mustafa, Anders, Carey K., Lascola, Christopher D., Hsu, Liangge, Lin, Nancy U., Sammons, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063529/
https://www.ncbi.nlm.nih.gov/pubmed/36997605
http://dx.doi.org/10.1038/s41523-023-00519-0
_version_ 1785017724086255616
author Alder, Laura
Trapani, Dario
Bradbury, Claire
Van Swearingen, Amanda E. D.
Tolaney, Sara M.
Khasraw, Mustafa
Anders, Carey K.
Lascola, Christopher D.
Hsu, Liangge
Lin, Nancy U.
Sammons, Sarah
author_facet Alder, Laura
Trapani, Dario
Bradbury, Claire
Van Swearingen, Amanda E. D.
Tolaney, Sara M.
Khasraw, Mustafa
Anders, Carey K.
Lascola, Christopher D.
Hsu, Liangge
Lin, Nancy U.
Sammons, Sarah
author_sort Alder, Laura
collection PubMed
description Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
format Online
Article
Text
id pubmed-10063529
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100635292023-04-01 Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan Alder, Laura Trapani, Dario Bradbury, Claire Van Swearingen, Amanda E. D. Tolaney, Sara M. Khasraw, Mustafa Anders, Carey K. Lascola, Christopher D. Hsu, Liangge Lin, Nancy U. Sammons, Sarah NPJ Breast Cancer Brief Communication Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active. Nature Publishing Group UK 2023-03-30 /pmc/articles/PMC10063529/ /pubmed/36997605 http://dx.doi.org/10.1038/s41523-023-00519-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Alder, Laura
Trapani, Dario
Bradbury, Claire
Van Swearingen, Amanda E. D.
Tolaney, Sara M.
Khasraw, Mustafa
Anders, Carey K.
Lascola, Christopher D.
Hsu, Liangge
Lin, Nancy U.
Sammons, Sarah
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title_full Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title_fullStr Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title_full_unstemmed Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title_short Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
title_sort durable responses in patients with her2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063529/
https://www.ncbi.nlm.nih.gov/pubmed/36997605
http://dx.doi.org/10.1038/s41523-023-00519-0
work_keys_str_mv AT alderlaura durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT trapanidario durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT bradburyclaire durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT vanswearingenamandaed durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT tolaneysaram durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT khasrawmustafa durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT anderscareyk durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT lascolachristopherd durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT hsuliangge durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT linnancyu durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan
AT sammonssarah durableresponsesinpatientswithher2breastcancerandleptomeningealmetastasestreatedwithtrastuzumabderuxtecan

Ejemplares similares